NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent

被引：208
|
作者：
Nicholson, B
Lloyd, GK
Miller, BR
Palladino, MA
Kiso, Y
Hayashi, Y
Neuteboom, STC
机构：
[1] Nereus Pharmaceut Inc, San Diego, CA 92121 USA
[2] Kyoto Pharmaceut Univ, Kyoto 607, Japan
来源：
ANTI-CANCER DRUGS | 2006年 / 17卷 / 01期
关键词：
cancer; natural product; NPI-2358; tubulin-depolymerizing agent; vascular-disrupting agent;
D O I：
10.1097/01.cad.0000182745.01612.8a
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The diketopiperazine NPI-2358 is a synthetic analog of NPI-2350, a natural product isolated from Aspergillus sp., which depolymerizes microtubules in A549 human lung carcinoma cells. Although structurally different from the colchicine-binding site agents reported to date, NPI-2358 binds to the colchicine-binding site of tubulin. NPI-2358 has potent in-vitro anti-tumor activity against various human tumor cell lines and maintains activity against tumor cell lines with various multidrug-resistant (MDR) profiles. In addition, when evaluated in proliferating human umbilical vein endothelial cells (HUVECs), concentrations as low as 10 nmol/l NPI-2358 induced tubulin depolymerization within 30 min. Furthermore, NPI-2358 dose dependently increases HUVEC monolayer permeability-an in-vitro model of tumor vascular collapse. NPI-2358 was compared with three tubulin-depolymerizing agents with vascular-disrupting activity: colchicine, vincristine and combretastatin A-4 (CA4). Results showed that the activity of NPI-2358 in HUVECs was more potent than either colchicine or vincristine; the profile of CA4 approached that of NPI-2358. Altogether, our data show that NPI-2358 is a potent anti-tumor agent which is active in MDR tumor cell lines, and is able to rapidly induce tubulin depolymerization and monolayer permeability in HUVECs. These data warrant further evaluation of NPI-2358 as a vascular-disrupting agent in vivo. Currently, NPI-2358 is in preclinical development for the treatment of cancer.
引用
收藏
页码：25 / 31
页数：7
相关论文
共 38 条
  • [21] Quantitative Evaluation of Tumor Early Response to a Vascular-Disrupting Agent with Dynamic PET
    Ning Guo
    Fan Zhang
    Xiaomeng Zhang
    Jinxia Guo
    Lixin Lang
    Dale O. Kiesewetter
    Gang Niu
    Quanzheng Li
    Xiaoyuan Chen
    Molecular Imaging and Biology, 2015, 17 : 865 - 873
  • [22] Quantitative Evaluation of Tumor Early Response to a Vascular-Disrupting Agent with Dynamic PET
    Guo, Ning
    Zhang, Fan
    Zhang, Xiaomeng
    Guo, Jinxia
    Lang, Lixin
    Kiesewetter, Dale O.
    Niu, Gang
    Li, Quanzheng
    Chen, Xiaoyuan
    MOLECULAR IMAGING AND BIOLOGY, 2015, 17 (06) : 865 - 873
  • [23] ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy
    Baguley, Bruce C.
    McKeage, Mark J.
    FUTURE ONCOLOGY, 2010, 6 (10) : 1537 - 1543
  • [24] The microtubule-binding agent pretubulysin exhibits profound vascular-disrupting properties in vitro
    Kretzschmann, V.
    Ullrich, A.
    Zahler, S.
    Vollmar, A. M.
    Kazmaier, U.
    Fuerst, R.
    JOURNAL OF VASCULAR RESEARCH, 2011, 48 : 113 - 113
  • [25] Biphasic anti-tumoral effect of a vascular-disrupting agent triggering STING and tumor regression
    Weiss, Julia M.
    Guerin, Marion
    Regnier, Fabienne
    Thoreau, Maxime
    Peranzoni, Elisa
    Feuillet, Vincent
    Renault, Gilles
    Guilbert, Thomas
    Trautmann, Alain
    Bercovici, Nadege
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (03)
  • [26] Assessment of pharmacodynamic effect in a Phase I study of NPI-2358, an IV administered vascular disruptive agent, using dynamic contrast-enhanced MRI
    Ashton, E.
    Lloyd, K.
    Spear, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 131 - 131
  • [27] The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities
    Head, Michelle
    Jameson, Michael B.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (02) : 295 - 304
  • [28] Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts
    Seshadri, Mukund
    Mazurchuk, Richard
    Spernyak, Joseph A.
    Bhattacharya, Arup
    Rustum, Youcef M.
    Bellnier, David A.
    NEOPLASIA, 2006, 8 (07): : 534 - 542
  • [29] MPC-6827: A potent tubulin binding and vascular disrupting agent with high brain penetration and anti-tumor activity in a mouse orthotopic glioma model
    Jones, Joshua
    Pleiman, Christopher
    McConville, Patrick
    Baranski, Jeni
    Roth, Bruce
    Baichwal, Vijay
    Scholl, Jason
    Mather, Gary
    Yu, Margaret
    CANCER RESEARCH, 2009, 69
  • [30] Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment
    Liu, Li
    Schuetze, Regan
    Gerberich, Jeni L.
    Lopez, Ramona
    Odutola, Samuel O.
    Tanpure, Rajendra P.
    Charlton-Sevcik, Amanda K.
    Tidmore, Justin K.
    Taylor, Emily A-S
    Kapur, Payal
    Hammers, Hans
    Trawick, Mary Lynn
    Pinney, Kevin G.
    Mason, Ralph P.
    CANCERS, 2022, 14 (17)
1234